Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MTCR - Metacrine Inc

Previous close
0.5814
0   0%

Share volume: 83,889
Last Updated: Tue 20 Jun 2023 06:00:00 AM CEST
Pharmaceutical Preparation Manufacturing : -2.88%

PREVIOUS CLOSE
CHG
CHG%
$0.58
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
57%
Profitability 68%
Dept financing 0%
Liquidity 0%
Performance 75%
Performance
5 Days
2.18%
1 Month
2.43%
3 Months
1.98%
6 Months
18.41%
1 Year
18.41%
2 Year
18.41%
Key data
Stock price
$0.58
P/E Ratio 
0.00
DAY RANGE
$0.58 - $0.58
EPS 
$0.00
52 WEEK RANGE
$0.42 - $0.59
52 WEEK CHANGE
$0.18
MARKET CAP 
24.750 M
YIELD 
N/A
SHARES OUTSTANDING 
42.570 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$73,358
AVERAGE 30 VOLUME 
$60,790
Company detail
CEO:
Region: US
Website: metacrine.com
Employees: 32
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

metacrine is a privately held biotech company founded in 2015 on technology licensed from the laboratory of dr. ronald evans, a world leader in nuclear hormone receptors and howard hughes medical institute investigator at the salk institute. metacrine will leverage two mechanistically distinct programs to target diabetes, steatohepatitis and other metabolic and liver disorders.

Recent news